Novartis publishes updated 2022 segment financial reporting
April 26, 2023
Today Novartis has published updated 2022 quarterly and full year segment financials reflecting transfers of Sandoz biotechnology manufacturing services to other companies’ activities and the Coartem® brand from Sandoz to the Innovative Medicines Division, which were effective as of January 1, 2023. The 2022 updated segment financial reporting is provided in accordance with requirements of IFRS, and to aid comparability of 2023 quarterly and full year results for the segments and Corporate.
Download the presentation (PDF 0.4 MB)